Lipocine Inc.
LPCN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -31.18 | -0.02 | -0.00 | 0.90 |
| FCF Yield | -5.03% | -80.80% | -35.80% | -7.94% |
| EV / EBITDA | -17.82 | -0.55 | -2.86 | -127.75 |
| Quality | ||||
| ROIC | -5.09% | -88.03% | -33.79% | 6.40% |
| Gross Margin | 100.00% | 456.92% | -1,611.38% | 52.51% |
| Cash Conversion Ratio | -146.22 | 0.73 | 1.11 | 6.95 |
| Growth | ||||
| Revenue 3-Year CAGR | 181.88% | – | – | 360.78% |
| Free Cash Flow Growth | 88.96% | 1.85% | -173.88% | 71.12% |
| Safety | ||||
| Net Debt / EBITDA | 5.57 | 0.27 | 0.29 | 1.49 |
| Interest Coverage | 0.00 | 0.00 | -447.24 | 15.47 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 3.93 | -56.77 | 456.08 | -55.80 |